Literature DB >> 7539979

Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies.

F Boege1, A Andersen, S Jensen, R Zeidler, H Kreipe.   

Abstract

Proliferation-linked expression of the nuclear Ki-S1 antigen is a significant prognostic indicator in mammary carcinomas. Here, we show staining of a protein of 170 kd by Ki-S1 antibody in immunoblots of Saccharomyces cerevisiae expressing human topoisomerase II alpha but not in the parental strain. In HL-60 cells containing both isoforms of human topoisomerase II, Ki-S1 antibody binds selectively to the 170-kd isoenzyme in a similar fashion as peptide-antibodies directed against amino acid residues 1 to 15 or 1512 to 1530 of human topoisomerase II alpha. Conversely, antibodies directed against carboxyl-terminal sequences of human topoisomerase II beta selectively stain a 180-kd protein. The immunoreactive pattern of V8 endoproteinase restriction digests of human topoisomerase II alpha was identical for Ki-S1-antibody and peptide-antibodies directed against residues 1512 to 1530 but different for peptide-antibodies directed against residues 1 to 15. The Rf values of the smallest fragment commonly recognized by Ki-S1 antibody and the carboxy terminus-specific peptide-antibody place the Ki-S1 epitope within the last 495 carboxyl-terminal amino acid residues of topoisomerase II alpha.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539979      PMCID: PMC1870919     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

1.  The distribution of immunoreactive topoisomerase II Protein in human tissues and neoplasms.

Authors:  J A Holden; D H Rolfson; C T Wittwer
Journal:  Oncol Res       Date:  1992       Impact factor: 5.574

2.  The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant.

Authors:  N Zini; A M Martelli; P Sabatelli; S Santi; C Negri; G C Astaldi Ricotti; N M Maraldi
Journal:  Exp Cell Res       Date:  1992-06       Impact factor: 3.905

3.  Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.

Authors:  D M Sullivan; M D Latham; W E Ross
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

4.  Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22.

Authors:  M Tsai-Pflugfelder; L F Liu; A A Liu; K M Tewey; J Whang-Peng; T Knutsen; K Huebner; C M Croce; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

5.  Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins.

Authors:  S M Davies; C N Robson; S L Davies; I D Hickson
Journal:  J Biol Chem       Date:  1988-11-25       Impact factor: 5.157

6.  Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.

Authors:  F H Drake; J P Zimmerman; F L McCabe; H F Bartus; S R Per; D M Sullivan; W E Ross; M R Mattern; R K Johnson; S T Crooke
Journal:  J Biol Chem       Date:  1987-12-05       Impact factor: 5.157

Review 7.  DNA topoisomerases as targets for chemotherapy.

Authors:  K M Rose
Journal:  FASEB J       Date:  1988-06       Impact factor: 5.191

8.  Topoisomerase II as a target of antileukemic drugs.

Authors:  L A Zwelling; E Estey; M Bakic; L Silberman; D Chan
Journal:  NCI Monogr       Date:  1987

9.  Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development.

Authors:  G Capranico; S Tinelli; C A Austin; M L Fisher; F Zunino
Journal:  Biochim Biophys Acta       Date:  1992-08-17

Review 10.  DNA topoisomerases in cancer therapy.

Authors:  R B Lock; W E Ross
Journal:  Anticancer Drug Des       Date:  1987-10
View more
  22 in total

1.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

Authors:  T A Järvinen; M Tanner; V Rantanen; M Bärlund; A Borg; S Grénman; J Isola
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  p53 regulates the minimal promoter of the human topoisomerase IIalpha gene.

Authors:  M I Sandri; R J Isaacs; W M Ongkeko; A L Harris; I D Hickson; M Broggini; F Vikhanskaya
Journal:  Nucleic Acids Res       Date:  1996-11-15       Impact factor: 16.971

4.  Topoisomerase II alpha mRNA and tumour cell proliferation in non-Hodgkin's lymphoma.

Authors:  A Lohri; J Reuter; F Gudat; R Herrmann
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

5.  [Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67].

Authors:  M Christgen; W Winkens; H H Kreipe
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

6.  Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction.

Authors:  U Lehmann; S Glöckner; W Kleeberger; H F von Wasielewski; H Kreipe
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

7.  Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms.

Authors:  H Biersack; S Jensen; I Gromova; I S Nielsen; O Westergaard; A H Andersen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

Review 8.  [Ki67: biological intertumor variance versus variance of assay].

Authors:  H Kreipe
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

Review 9.  Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Authors:  Atocha Romero; Miguel Martín; Maggie C U Cheang; José Antonio López García-Asenjo; Belén Oliva; Xiaping He; Miguel de la Hoya; Jose Ángel García Sáenz; Manuel Arroyo Fernández; Eduardo Díaz Rubio; Charles M Perou; Trinidad Caldés Llopis
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

10.  The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage.

Authors:  Timothy J Wendorff; Bryan H Schmidt; Pauline Heslop; Caroline A Austin; James M Berger
Journal:  J Mol Biol       Date:  2012-07-25       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.